Mounjaro (tirzepatide) works by activating two gut hormone receptors at once, mimicking the natural signals your body sends after eating to control blood sugar, slow digestion, and reduce appetite. It’s the first medication in its class to target both GIP and GLP-1 receptors, which is why it produces stronger effects on blood sugar and weight than drugs targeting only one of those pathways. The FDA has approved it for improving blood sugar control in adults and children 10 and older with type 2 diabetes.
The Dual Hormone System
Your gut naturally releases two hormones after you eat: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones tell your pancreas to release insulin when blood sugar rises, but they do it through separate receptors and slightly different signaling pathways. Older medications like semaglutide (Ozempic, Wegovy) activate only the GLP-1 receptor. Mounjaro activates both.
This dual action matters because the two hormones complement each other. GLP-1 suppresses glucagon, a hormone that raises blood sugar, when glucose levels are already high. GIP takes a different approach during low blood sugar, actually supporting glucagon release to prevent levels from dropping too far. Working together, these signals help keep blood sugar in a tighter, more stable range than either hormone could achieve alone. Both hormones also share overlapping effects on the brain’s satiety center, influencing how hungry you feel between meals.
How It Reduces Appetite
Much of Mounjaro’s effect on weight comes from changes in the brain, not just the gut. Research from Northwestern University has shown that drugs acting on GIP and GLP-1 receptors suppress a specific group of neurons in the hypothalamus called AgRP neurons. These neurons normally fire up when you’re losing weight, sending strong “you need to eat” signals. Mounjaro silences them, reducing that drive.
At the same time, the drug activates neurons in the brainstem that signal fullness. So it works on both sides of the equation: it tells your brain you’re full and prevents the compensatory hunger signals that typically kick in when you start losing weight. Interestingly, researchers found that GIP, not GLP-1, is the key player in communicating with those appetite-driving AgRP neurons. The effect appears to be indirect, traveling through a circuit scientists are still mapping, since AgRP neurons don’t actually have GIP receptors on their surface. This may be one reason Mounjaro’s dual approach produces more weight loss than GLP-1-only drugs.
Slowing Stomach Emptying
Mounjaro also slows the rate at which food leaves your stomach. This does two things: it reduces the spike in blood sugar you’d normally see after a meal, and it keeps you feeling physically full for longer. The delay is most pronounced after your first dose and gradually lessens over time as your body adjusts, which is one reason the starting dose is low.
This slower gastric emptying is also the main source of the drug’s most common side effects. Up to 22% of people in clinical trials experienced nausea, 12% to 17% had diarrhea, and about 1 in 10 reported vomiting. Constipation affected roughly 1 in 13 people. These symptoms tend to be worst during the early weeks and around dose increases, then improve as your body adapts to each new level.
What the Clinical Trials Show
The weight loss results from the SURMOUNT-1 trial, which studied Mounjaro in people with obesity or overweight (without diabetes), were striking. Over 72 weeks, participants lost an average of 15% of their body weight on the lowest dose (5 mg), 19.5% on the middle dose (10 mg), and 20.9% on the highest dose (15 mg), compared to placebo. For someone weighing 250 pounds, that highest dose translates to roughly 52 pounds lost over about a year and a half.
For blood sugar control in type 2 diabetes, the SURPASS trials consistently showed that Mounjaro outperformed both placebo and existing treatments. Up to 92% of participants reached an A1C below 7%, which is the target most guidelines recommend for people with diabetes. Even more notable, up to 51% to 62% of participants (depending on the trial) reached an A1C below 5.7%, a level typical of someone without diabetes at all. In head-to-head comparisons, Mounjaro delivered better A1C reductions and more weight loss than both semaglutide and long-acting insulin.
On the cardiovascular side, a large outcomes trial called SURPASS-CVOT found that Mounjaro was at least as protective against major cardiovascular events (heart attack, stroke, and cardiovascular death) as another diabetes drug already shown to reduce cardiovascular risk.
How the Dosing Works
Mounjaro is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm. Everyone starts at 2.5 mg for the first four weeks. This initial dose isn’t really a treatment dose; it’s a ramp-up period to let your digestive system adjust. After four weeks, the dose increases to 5 mg.
From there, your prescriber can increase in 2.5 mg steps every four weeks or longer, based on how well your blood sugar is responding and how you’re tolerating side effects. The maximum dose is 15 mg per week. Not everyone needs to reach the top dose. Some people get adequate blood sugar control or weight loss at 5 mg or 10 mg. The gradual escalation is specifically designed to minimize the nausea and GI symptoms that come with the drug’s effect on stomach emptying, giving your body time to adjust at each level before moving up.
Why Dual Action Outperforms Single
The key question most people have is why Mounjaro tends to produce better results than GLP-1-only drugs. The answer lies in how GIP and GLP-1 use overlapping but distinct signaling pathways inside cells. Both receptors belong to the same family, and both trigger a shared pathway that boosts insulin release. But they also activate unique downstream signals that the other doesn’t, which means hitting both receptors produces effects that aren’t simply doubled but genuinely different.
GIP’s role in appetite suppression through the hypothalamus, its ability to support glucagon during low blood sugar (potentially reducing hypoglycemia risk), and its additive effects on insulin secretion all contribute to outcomes that go beyond what GLP-1 activation alone can deliver. The combination also appears to produce greater improvements in insulin sensitivity and fat metabolism, which helps explain the larger reductions in both body weight and blood sugar seen across Mounjaro’s clinical trials.